The listed entity is Charming Medical Ltd (Meiyantang), with its headquarters located in Hong Kong, and it is ultimately listed on the NASDAQ Stock Exchange in the United States under the ticker symbol MCTA. November 21, 2024: Submitted a confidential filing to the U.S. Securities and Exchange Commission (SEC); May 14, 2025: Publicly disclosed the prospectus (official prospectus link: https://www.sec.gov/Archives/edgar/data/2035992/000121390025100671/ea0213012-11.htm, registration number 333-287258); October 21, 2025: Officially listed on NASDAQ and completed the listing trading. Details of Meiyantang’s listing offering this time are as follows: Offering price: US$4 per share; Number of shares offered: 1.6 million Class A ordinary shares; Total proceeds raised: US$6.4 million (calculated based on the offering price, excluding underwriting fees and other related costs). Meiyantang is a traditional Chinese medicine (TCM)-driven physiotherapy and product supplier, with its core business focused on women’s health. Its specific layout covers three aspects: 1. Health physiotherapy services: Through 4 health physiotherapy centers in Hong Kong, it provides services such as uterine warming physiotherapy, pelvic detoxification physiotherapy, moxibustion, prenatal massage, traditional abdominal binding, etc., targeting women’s needs for physiological disorders, hormonal imbalance and postnatal recovery; 2. Product R&D and sales: Under the brand "Beauty Lab", it launches dietary supplements and beauty products inspired by TCM concepts, including uterine warming patches, probiotic intimate care washes, nourishing herbal formulas, etc., to help improve women’s physical fitness and vitality; 3. Ecological expansion services: Provide professional technical training, dietary therapy consultation and franchise opportunities to promote its own health concepts to more practitioners and entrepreneurs. Chairman and Chief Executive Officer (CEO): Kit Wong, who has rich experience in postnatal recovery, beauty health and TCM long-term health care, and also serves as an independent director of several subsidiary companies; Chief Financial Officer (CFO): Ching Man Cheung, who has nearly 20 years of experience in accounting and financial management, and is a member of the Hong Kong Institute of Certified Public Accountants (HKICPA); Independent director candidates: Leut Ming Gung (senior figure in the financial industry, former financial strategy advisor of Guotai Junan International), Josephine Yan Yeung (with more than 20 years of accounting and audit experience, Hong Kong practicing CPA), Shu Tai Victor Yu (Hong Kong registered Chinese medicine practitioner, specialized in acupuncture, orthopedics and other fields), who will officially take office after the listing. Opening price: US$4.59; Closing price: US$7.00, surging 75% compared to the offering price (US$4); After-hours price: US$6.75, down 3.50% from the closing price; Highest price of the day: US$8.21 (52-week high), lowest price: US$4.30 (52-week low), with an amplitude of 97.75%. Trading volume: 4.2187 million shares; Trading amount: US$27.6626 million; Total market capitalization: Approximately US$119 million (calculated based on the closing price); Total share capital: 16.938 million shares; Turnover rate: 24.91%. Earnings per share (EPS): US$0.07; Price-to-earnings ratio (TTM / static): 98.88 times; Price-to-book ratio: 2407.77 times; No dividend (TTM), dividend yield and institutional shareholding ratio data are available yet. © 2021 Meishun (Hong Kong) Management Consulting Co., Ltd. and Meishun (Hangzhou) Management Consulting Co., Ltd. All rights reserved. Meishun Meiyin (Hangzhou) Consulting and Management Co., Ltd. is a domestic subsidiary of Hong Kong Meishun Management Consulting Co., Ltd. under the same ultimate beneficial owner. Both companies are under the same actual controller, all companies are managed under a unified Chinese governance framework, and comply with the laws of Hong Kong and mainland China.